Drug Search Results
More Filters [+]

SGT-53

Alternative Names: sgt-53, sgt53, sgt 53
Latest Update: 2023-12-03
Latest Update Note: PubMed Publication

Product Description

SGT-53 is a complex composed of a wild type p53 gene (plasmid DNA) encapsulated in a liposome that is targeted to tumor cells by means of an anti-transferrin receptor single-chain antibody fragment (TfRscFv) attached to the outside of the liposome. Pre-clinical studies have indicated that SGT-53 could sensitize tumors to the effects of radiation/chemotherapy. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00470613)

Mechanisms of Action: Gene Therapy

Novel Mechanism: No

Modality: Gene Therapy

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SGT-53

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Glioblastoma|Pancreatic Cancer

Phase 1: Inflammatory Breast Cancer|Liver Cancer|Bone Cancer|Oncology Unspecified|Rhabdomyosarcoma|Triple Negative Breast Cancer|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SGT53-00-1

P1

Unknown status

Oncology Unspecified

2023-12-01

27%

SGT53-02-1

P2

Unknown status

Pancreatic Cancer

2022-12-01

57%

SGT53-01-2

P1

Suspended

Bone Cancer|Liver Cancer|Rhabdomyosarcoma

2022-12-01

43%

NU 19B07

P1

Withdrawn

Inflammatory Breast Cancer|Triple Negative Breast Cancer

2022-11-10

Recent News Events